The news of Oppenheimer maintaining an Outperform rating and raising the price target for Rentokil Initial is positive for the stock. This indicates that the analyst believes the company will perform better than its peers in the market. The increase in the price target from $40 to $47 suggests that the analyst sees potential for the stock to appreciate in value. This news is likely to have a positive impact on the stock price in the short term.